

From: [Gareth Sheridan](#)
To: [Hassan Almoazen](#)
Subject: Re: update
Date: Monday, April 30, 2018 4:07:32 PM
Attachments: [image001.png](#)

That would be great Hassan thanks!

[Gareth Sheridan](#)

CEO
Nutriband Inc.
www.nutriband.com
gareth@nutriband.com
EU - (00353) 87 6160959
USA - (001) 385-881-3385



GARETH SHERIDAN

CEO | Nutriband Inc

mobile: [+1 385 881 3385](tel:+13858813385)

site: www.nutriband.com

email: gareth@nutriband.com



The information contained in this communication is the property of Nutriband Inc., may constitute inside information and is only intended for use by the addressee. Unauthorised use, disclosure, copying or reliance upon the contents of this communication, or any part thereof, is strictly prohibited and may be unlawful. If you have received this communication in error please destroy this communication, or copies thereof, including all attachments.

On Mon, Apr 30, 2018 at 4:06 PM, Hassan Almoazen <halmoazen@ionopharma.com> wrote:

Gareth,

The iodide delivery is in two published papers, the clindamycin project is in two published papers, the US patent has been filed and should be published in few weeks. We finished the animal study and the results are in a manuscript (in preparation) which we plan to publish this year. The epinephrine project is in a PCT which will be published next month. I can send you the papers if you like to see them?

Hassan

Hassan Almoazen PhD

Founder and Chief Scientific Officer

Iono Pharma LLC

Memphis, Tennessee 38135

Tel: [\(901\)-448-2239](tel:(901)448-2239)

Email: halmoazen@ionopharma.com



www.ionopharma.com

From: Gareth Sheridan [mailto:gareth@nutriband.com]

Sent: Monday, April 30, 2018 2:43 PM

To: Hassan Almoazen <halmoazen@ionopharma.com>

Subject: Re: update

Have you got a data room for each product or a folder outlining any pre clinicals / testing / formulas etc which I can run past the Scientific management to check opportunities?

Happy to sign a new NDA if you like also

Gareth Sheridan

CEO

Nutriband Inc.

www.nutriband.com

gareth@nutriband.com

EU - (00353) 87 6160959

USA - (001) 385-881-3385



GARETH SHERIDAN

CEO | Nutriband Inc

mobile: [+1 385 881 3385](tel:+13858813385)

site: www.nutriband.com

email: gareth@nutriband.com



The information contained in this communication is the property of Nutriband Inc., may constitute inside information and is only intended for use by the addressee. Unauthorised use, disclosure, copying or reliance upon the contents of this communication, or any part thereof, is strictly prohibited and may be unlawful. If you have received this communication in error please destroy this communication, or copies thereof, including all attachments.

On Wed, Apr 25, 2018 at 3:05 PM, Hassan Almoazen <halmoazen@ionopharma.com> wrote:

No problem. Let me know which product you are interested in and what are your ideas to move forward with the product(s)?

Hassan

Hassan Almoazen PhD.

Founder and Chief Scientific Officer

Iono Pharma LLC

Memphis, Tennessee 38135

Tel: (901)-448-2239

Email: halmoazen@ionopharma.com



www.ionopharma.com

From: Gareth Sheridan <gareth@nutriband.com>

Sent: Wednesday, April 25, 2018 1:42 PM

To: Hassan Almoazen <halmoazen@ionopharma.com>

Subject: Re: update

No new products to market yet, all are still in clinical pipeline at various stages.

Perhaps we can work together if not from an acquisition point as previously rejected but from a co development / licensing opp

Gareth Sheridan

CEO

Nutriband Inc.

www.nutriband.com

gareth@nutriband.com

EU - (00353) 87 6160959

USA - (001) 385-881-3385

The information contained in this communication is the property of Nutriband Inc., may constitute inside information and is only intended for use by the addressee. Unauthorized use, disclosure, copying or reliance upon the contents of this communication, or any part thereof, is strictly prohibited and may be unlawful. If you have received this communication in error please destroy this communication, or copies thereof, including all attachments.

On Wed, Apr 25, 2018 at 1:44 PM, Hassan Almoazen <halmoazen@ionopharma.com> wrote:

I have contacted few large companies about potential joint development or licensure agreements and some declined and others still pending. I will need to file in the US within one year and continue to talk to people. Have you taken any new products to market?

Hassan

Hassan Almoazen PhD

Founder and Chief Scientific Officer

Iono Pharma LLC

Memphis, Tennessee 38135

Tel: [\(901\)-448-2239](tel:(901)448-2239)

Email: halmoazen@ionopharma.com



www.ionopharma.com

From: Gareth Sheridan [mailto:gareth@nutriband.com]

Sent: Wednesday, April 25, 2018 11:32 AM

To: Hassan Almoazen <halmoazen@ionopharma.com>

Subject: Re: update

Nice, has there been further inquiries or license opportunities being explored?

How's the fundraising going with investors?

What's the plans going forward following the filing of the IP

All good or end, we recently completed the acquisition of 4P THERapeutics in Atlanta so great progress there

Gareth Sheridan

CEO

Nutriband Inc.

www.nutriband.com

gareth@nutriband.com

EU - (00353) 87 6160959

USA - (001) 385-881-3385

The information contained in this communication is the property of Nutriband Inc., may constitute inside information and is only intended for use by the addressee. Unauthorized use, disclosure, copying or reliance upon the contents of this communication, or any part thereof, is strictly prohibited and may be unlawful. If you have received this communication in error please destroy this communication, or copies thereof, including all attachments.

On Wed, Apr 25, 2018 at 12:24 PM, Hassan Almoazen
<halmoazen@ionopharma.com> wrote:

Hi Gareth,

Nothing much to say except the IP have been filed for Epinephrine and Clindamycin.
How things going for you?

Hassan

Hassan Almoazen PhD

Founder and Chief Scientific Officer

Iono Pharma LLC

Memphis, Tennessee 38135

Tel: [\(901\)-448-2239](tel:(901)448-2239)

Email: halmoazen@ionopharma.com



www.ionopharma.com

From: Gareth Sheridan [mailto:gareth@nutriband.com]

Sent: Wednesday, April 25, 2018 11:20 AM

To: Hassan Almoazen <halmoazen@ionopharma.com>

Subject: update

Hassan, long time, hows things going with Iono?

Best,

[Gareth Sheridan](#)

CEO

Nutriband Inc.

www.nutriband.com

gareth@nutriband.com

EU - (00353) 87 6160959

USA - (001) 385-881-3385

The information contained in this communication is the property of Nutriband Inc., may constitute inside information and is only intended for use by the addressee. Unauthorized use, disclosure, copying or reliance upon the contents of this communication, or any part thereof, is strictly prohibited and may be unlawful. If you have received this communication in error please destroy this communication, or copies thereof, including all attachments.